BlackRock Health Sciences Trust is an attractively valued fund with a 53% margin of safety, strong margins and a 7.0% dividend, in a breakout near its 52-week high, though revenue is declining and there is no analyst coverage.
Thesis pillars
- Margin Of Safety Valuation→Stable
- Breakout Above All Averages→Stable
- High Dividend With Safety→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026
Blackrock Health Sciences Trust (BME) Stock Analysis
Inst Constrain edge
Financial Services · Asset Management
Hold if already holding. Not a fresh buy at $45.96, but acceptable to hold if already in. Reasons: Near 52-week high (1.0% away); Weak growth.
BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health... Read more
Hold if already holding. Not a fresh buy at $45.96, but acceptable to hold if already in. Reasons: Near 52-week high (1.0% away); Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — Blackrock Health Sciences Trust
Latest news
- NEWS Berenberg Boosts B&M European Value Retail Price Target, Maintains Buy Rating — fiscal.ai Oct 27, 2026 neutral
- NEWS Jefferies Reaffirms Neutral Rating on B&M European Value Retail plc — fiscal.ai Oct 22, 2026 neutral
- NEWS B&M European Value Retail Reportedly Interested in Acquiring Select Poundland Stores — fiscal.ai Oct 20, 2026 neutral
Generated 2026-10-29T11:14:31Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Revenue shrinking — -3.8% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $45.96, but acceptable to hold if already in. Reasons: Near 52-week high (1.0% away); Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Default target $52.85 (+15.0%), stop $44.44 (−3.4%), A.R:R 0.0:1. Score 5.9/10, moderate confidence.
Default target: $52.85 (+15.0% upside). Default target $52.85 (+15.0%), stop $44.44 (−3.4%), A.R:R 0.0:1. Stop-loss: $44.44.
Near 52-week high (1.0% away); Weak growth.
Blackrock Health Sciences Trust trades at a P/E of 5.7 (forward N/A). TrendMatrix value score: 9.9/10. Verdict: Hold.
What does Blackrock Health Sciences Trust do?BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by...
BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.